MarketWatch (press release) METROGEL 1% should be used with caution in patients with evidence of, or a history of, blood dyscrasia, and with patients taking blood thinning agents as they may experience prolonged prothrombin times. METROGEL 1% treatment should be ... Galderma is a ... and more »
Medical Xpress The primary task of the immune system is to defend its host against infectious agents and tumors. So-called T cells play a crucial role in this process, because they carry surface receptors that recognize and bind to ... A team led by Privatdozent Dr ...
Durham Herald Sun Stiefel Laboratories was the world's largest privately held pharmaceutical company specializing in dermatological products, with nearly 4,000 employees in 30 countries, before it was sold to GlaxoSmithKline in 2009 for $3.6 billion, according to the ... and more »
Patent Docs About the Authors. The Authors and Contributors of "Patent Docs" are patent attorneys and agents who hold doctorates in a diverse array of biotech and chemical disciplines. ... In 2009, SkinMedica filed suit against Histogen for producing ...
MarketWatch These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura (ITP) pending discussions with regulatory agencies . Rigel believes that a Phase 3 ... Rigel's other two lead programs ... and more »
Genetic Engineering News “The company will not continue further development of fostamatinib for the treatment of rheumatoid arthritis or lymphoma due to insufficient efficacy findings from recent clinical trials and the competitive landscape for the agent in those indications ...
Healio Rigel Pharmaceuticals has announced plans to focus its resources on three lead clinical programs, including a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus. The San Francisco-based company will discontinue development of ...
Wall Street Journal (press release) "Germany is one of the largest markets in Europe for dermatological and skin care devices. Given the ... The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. and more »
PR Newswire (press release) Beyond lidocaine, the Alliqua Biomedical division plans to explore transdermal delivery of dermatological , oncology, antibiotic and neurology products." The Company plans to develop lidocaine hydrogel patches for the ... Alliqua's hydrogels can be ... and more »
